This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.

Breaking Barriers
To Precision Oncology

A visionary diagnostic company dedicated to transforming the landscape of cancer care. We are driven by innovation, accessibility, collaboration, and integrity.

Welcome to AmoyDx

A visionary diagnostic company dedicated to transforming the landscape of cancer care. 'Breaking Barriers to Precision Oncology' reflects our commitment to revolutionizing cancer diagnosis and treatment.

Innovation in Care: Developing groundbreaking diagnostic tools for precision oncology.

Accessibility and Equity: Ensuring advanced diagnostics are available globally.

Collaboration and Partnership: Working closely with pharma and clinical labs.

Integrity and Trust: Delivering reliable, accurate, and ethically developed solutions.

AmoyDx Lab

Our Mission & Vision

Our Mission

To provide our customers with superior and innovative products and services to improve healthcare and patients' lives.

Our Vision

To be one of the global leading and most reliable suppliers of high-quality molecular diagnostic solutions in oncology.

Core Technologies

Proprietary platforms enabling precision, speed, and accessibility in cancer diagnostics.

dC

ddCapture®

Every Strand Matters — highly efficient NGS library prep with minimal sample input.

H

HANDLE®

Making Complex NGS Testing Easy to HANDLE — simplified workflow for broad adoption.

A

ADx-ARMS®

No Sequencing Needed — rapid PCR-based mutation detection with high specificity.

S

Super-ARMS®

Sensitivity Increased to 0.2% — detects ultra-low frequency mutations in liquid biopsy.

Our Oncology Products

Comprehensive molecular diagnostic solutions for precision oncology.

HRD Focus Panel

AmoyDx® HRD Focus Panel

Leveraging HANDLE tech and GSS algorithm for accurate HRD scoring in PARPi therapy.

  • Technology: NGS
  • Biomarkers: HRD, BRCA1/2
  • Sample Type: FFPE, Blood
HRD Complete Panel

AmoyDx® HRD Complete Panel

Comprehensive HRD test for clinical research with full genomic scar analysis.

  • Technology: NGS
  • Biomarkers: HRD, TMB, MSI
  • Application: PARPi Trials
Master Panel

AmoyDx® Master Panel

Leading CGP assay covering HRD, MSI, TMB, and 500+ cancer genes.

  • Technology: NGS
  • Genes: 500+
  • Tumor Types: Pan-tumor
BRCA Pro Panel

AmoyDx® BRCA Pro Panel

Detects germline/somatic SNVs/Indels and large rearrangements in BRCA1/2.

  • Technology: NGS
  • Sample: Blood, FFPE
  • Use Case: Hereditary Cancer

AmoyDx® HANDLE Classic NGS Panel

40 key solid tumor genes for rapid clinical decision support.

  • Genes: 40
  • Turnaround: Fast TAT
  • Indications: NSCLC, CRC, Breast

AmoyDx® Essential NGS Panel

Detects key mutations in 10 genes for NSCLC and colorectal cancer.

  • Genes: EGFR, ALK, ROS1, KRAS, etc.
  • Sample: FFPE, Liquid Biopsy
  • Tumor: NSCLC, CRC

AmoyDx® Pan Lung Cancer PCR Panel

Approved in Japan as CDx for Lorlatinib, Taletrectinib, and Amivantamab.

  • Technology: PCR
  • Indications: ALK, ROS1, RET, MET
  • Regulatory: Approved in Japan

AmoyDx® HANDLE Breast Cancer Liquid NGS Panel

Performance evaluation completed for liquid biopsy-based breast cancer profiling.

  • Technology: NGS (Liquid)
  • Application: Monitoring, Resistance
  • Sample: Plasma

Resources & Webinars

Stay updated with the latest in molecular diagnostics and oncology testing.

Recent Webinars

  • Nov 8, 2023: Unlocking HRD's Secrets: Tools and Techniques for Detection
  • Oct 24, 2023: Innovations in MSI Detection: Unmasking a New Testing Solution
  • Aug 30, 2023: An Overview of the HRD Testing Landscape
  • May 5, 2023: Sample Diversification in Molecular Diagnostics

Latest News

  • Oct 8, 2025: Pan Lung PCR Panel submitted for Amivantamab+chemo approval in Japan
  • Sep 19, 2025: Approved in Japan as CDx for Taletrectinib
  • Aug 21, 2025: Approved as CDx for Lorlatinib
  • Jul 23, 2025: Approved for Amivantamab + Lazertinib combo

Get in Touch

For inquiries about our products, partnerships, or support, visit our official website.

Address: 2 Science Park Drive, Ascent #01-08, Singapore 118222

Email: info@amoydx.com

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact support@fobcompany.info

如果您是其他域名合作 也请联系support@fobcompany.info